Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. We have based these forward-looking statements on our current expectations and projections about future events. Private Securities Litigation Reform Act of 1995. This press release includes forward-looking statements, as defined in the U.S. sales of approximately $1.13 billion for the most recent twelve months ending June 2012 according to IMS Health*.ĭr.Reddy’s Metoprolol Succinate ER tablets in 25 mg, 50 mg, 100 mg and 200 mg are available in bottle counts of 100 and 500. The Toprol-XL® brand and generic had U.S. Metoprolol ER (Extended-Release) Tablets (25 mg, 50 mg, 100 mg, & 200 mg) was approved by the United States Food & Drug Administration (USFDA) in August 2012. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched Metoprolol Succinate ER (Extended-Release) Tablets (25 mg, 50 mg, 100 mg & 200 mg), a bioequivalent generic version of Toprol-XL® (Metoprolol Succinate) Tablets in the US market on September 11, 2012. Reddy’s Announces the Launch of Metoprolol Succinateĭr.
